Table 1.

Production of proinflammatory mediators from human PBMCs activated with VTX-2337, imiquimod, and CpG ODN2006

AnalyteMediator level (mean ± SEM), pg/mLEC50, nmol/L
ControlVTX-2337 (1,600 nmol/L)Imiquimod (25,000 nmol/L)CpG (1,500 nmol/L)VTX-2337ImiquimodCpG
G-CSF1.4 ± 0.997 ± 23.7a17 ± 12<1270>25,000NC
IL-1α1.3 ± 0.7321 ± 12747 ± 280.9 ± 0.8250>25,000NC
IL-1β9.1 ± 5.74,989 ± 1,560791 ± 4318.6 ± 4.4200>25,000NC
IFNγ0.5 ± 0.3785 ± 227a6.9 ± 6.9<1190>25,000NC
IL-662 ± 269,583 ± 3,4612,562 ± 1,266111 ± 5015018,60020
IL-8211 ± 1199,850 ± 4,72011,135 ± 6,4602,581 ± 1,4012016,90090
IL-100.9 ± 0.672 ± 2959 ± 245.5 ± 2.912017,00010
IL-12p405.7 ± 2.2140 ± 32a10.2 ± 3.55.5 ± 3.1230270NC
IL-12p70<0.538 ± 10a0.6 ± 0.60.6 ± 0.6220NCNC
MIP-1α188 ± 9115,258 ± 3,547a2,813 ± 1,261460 ± 200210>25,000360
MIP-1β289 ± 1144,262 ± 1,011a1,037 ± 402472 ± 169603,60030

Abbreviation: NC, not calculated.

  • aP < 0.05 relative to control.